Trial NCT04602117

View at ClinicalTrials.gov 
Org. Study IDs: ISPY-P1.01

Last trial update was posted on 2023-11-18

MeSH Interventions

Albumin-Bound Paclitaxel Paclitaxel Trastuzumab

MeSH Conditions

Breast Neoplasms Carcinoid Tumor Carcinoma Neoplasm Metastasis Neoplasms Neoplasms, Second Primary Triple Negative Breast Neoplasms

Other Conditions

Bladder Cancer Endometrium Tumor Estrogen Receptor Positive Tumor GastroEsophageal Cancer Gastroesophageal Adenocarcinoma HER-2 Protein Overexpression HER2 Low HER2 Low Breast Cancer HER2 Low HR Positive HER2 Mutation-Related Tumors HER2-positive Breast Cancer HER2-positive Gastric Cancer HER2-positive Metastatic Breast Cancer HR Positive Hormone Receptor Negative Breast Carcinoma Hormone Receptor-positive Breast Cancer Metastatic Metastatic Breast Cancer Metastatic Cancer Metastatic Gastrointestinal Carcinoid Tumor Ovarian Cancer Ovarian Carcinoma Progesterone Receptor-positive Breast Cancer SYD-985 SYD985 Triple Negative Breast Cancer Vic-trastuzumab Duocarmazine

Stopping Reasons

Study withdrawn as scientific interest in pursuing the SYD985+Paclitaxel combination has diminished.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID